A large clinical trial has found that giving the immunotherapy drug nivolumab (Opdivo) and chemotherapy to people with early-stage lung cancer before surgery can delay the return of their cancer and help increase the number of people with no cancer left in their lungs.
For some people with acute myeloid leukemia (AML) that has a mutation in the IDH1 gene, combining ivosidenib (Tibsovo) with the chemotherapy drug azacitidine may be a new treatment option, according to results from a large clinical trial.
Clinical Trials Information for Patients and Caregivers
Cancer clinical trials are often described in terms unfamiliar to people without a medical background. The terms below are often used to talk about types of clinical trials.
In this phase 2 trial, people between the ages of 1 and 25 with B-cell acute lymphoblastic leukemia will get a new kind of lab test to determine their likelihood of relapse after a blood stem cell transplant. Those with a low chance of relapse can get a pre-transplant treatment that omits total body radiation in favor of chemotherapy. Researchers want to see if the people receiving chemotherapy have similar event-free survival after two years.
This phase 2 clinical trial will test adding olaparib (Lynparza), a type of drug called a PARP inhibitor, to the chemotherapy drug temozolomide for people with certain neuroendocrine tumors (specifically, pheochromocytoma or paraganglioma) that have spread or that cannot be surgically removed. Doctors want to see if giving olaparib with temozolomide can shrink or stabilize the tumors better than temozolomide alone.
This phase 1 trial will test the safety and tolerability of nivolumab (Opdivo) to treat people with cancer who also have autoimmune disorders. Doctors will monitor the side effects and toxicity of nivolumab in people with various types of autoimmune diseases and cancer that has spread or that can’t be removed with surgery.
